Hememics Biotechnologies closes $2M in Seed 2 Financing

Daily Record Staff//May 25, 2023

Hememics Biotechnologies closes $2M in Seed 2 Financing

By Daily Record Staff

//May 25, 2023

Gaithersburg-based biotechnology company Hememics Biotechnologies Inc., developer of a handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, Thursday announced the closing of a $2 million Seed 2 financing round.

Participants of this round include a strategic investor, existing investors and TEDCO, the Maryland Technology Development Corporation.

Hememics  uses graphene-based sensors with its patented bio preservatives to bring handheld, lab-quality testing performance to wherever it is needed – whether it is a farm, emergency room or battlefield. Its platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets.


Networking Calendar

Submit an entry for the business calendar